Central venous access devices play an important role in patients with prolonged intravenous administration requirements. In the last years, the coating of these devices with bactericidal compounds has emerged as a potential tool to prevent bacterial colonization. Our study describes the modification of 3D-printed reservoirs and silicone-based catheters, mimicking central venous access devices, through different approaches including their coating with the well known biocompatible and bactericidal polymer chitosan, with the anionic polysaccharide alginate; also, plasma treated surfaces were included in the study to promote polymer adhesion. The evaluation of the antimicrobial action of those surface modifications compared to that exerted by a model antibiotic (ciprofloxacin) adsorbed on the surface of the devices was carried out. Surface characterization was developed by different methodologies and the bactericidal effects of the different coatings were assayed in an in vitro model of Staphylococcus aureus infection. Our results showed a significant reduction in the reservoir roughness (≤73%) after coating though no changes were observed for coated catheters which was also confirmed by scanning electron microscopy, pointing to the importance of the surface device topography for the successful attachment of the coating and for the subsequent development of bactericidal effects. Furthermore, the single presence of chitosan on the reservoirs was enough to fully inhibit bacterial growth exerting the same efficiency as that showed by the model antibiotic. Importantly, chitosan coating showed low cytotoxicity against human keratinocytes, human lung adenocarcinoma epithelial cells, and murine colon carcinoma cells displaying viability percentages in the range of the control samples (>95%). Chitosan-based coatings are proposed as an effective and promising solution in the prevention of microbial infections associated to medical devices.
ChauhanAGhigoJMBeloinC. Study of in vivo catheter biofilm infections using pediatric central venous catheter implanted in rat. Nat Protoc2016; 11: 525–541.
2.
VeenstraDLSaintSSahaS, et al.Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA1999; 281: 261–267.
3.
CheungEBaerlocherMOAschM, et al.Venous access: a practical review for 2009. Can Fam Physician2009; 55: 494–496.
4.
PittetDTararaDWenzelRP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA1994; 271: 1598–601.
5.
MermelLA. Prevention of intravascular catheter-related infections. Ann Intern Med2000; 132: 391–402.
6.
BaskinJLPuiCHReissU, et al.Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet2009; 374: 159–169.
7.
GallowaySBodenhamA. Long-term central venous access. Br J Anaesth2004; 92: 722–734.
8.
BaystonRBhundiaCAshrafW. Hydromer-coated catheters to prevent shunt infection?J Neurosurg2005; 102: 207–212.
9.
BowlerPGDuerdenBIArmstrongDG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev2001; 14: 244–269.
10.
Gilabert-PorresJMartíSCalatayudL, et al.Design of a nanostructured active surface against gram-positive and gram-negative bacteria through plasma activation and in situ silver reduction. ACS Appl Mater Interfaces2016; 8: 64–73.
11.
XuYJonesJEYuH, et al.Nanoscale plasma coating inhibits formation of Staphylococcus aureus biofilm. Antimicrob Agents Chemother2015; 59: 7308–7315.
12.
AmorenaBGraciaEMonzónM, et al.Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother1999; 44: 43–55.
13.
MonzónMGarcía-AlvarezFLaclérigaA, et al.Evaluation of four experimental osteomyelitis infection models by using precolonized implants and bacterial suspensions. Acta Orthop Scand2002; 73: 11–19.
14.
GraciaELaclérigaAMonzónM, et al.Application of a rat osteomyelitis model to compare in vivo and in vitro the antibiotic efficacy against bacteria with high capacity to form biofilms. J Surg Res1998; 79: 146–153.
15.
MonzónMGarcía-AlvarezFLaclérigaA, et al.A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment. J Orthop Res2001; 19: 820–826.
16.
Kokai-KunJFChanturiyaTMondJJ. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother2009; 64: 94–100.
KamalGDPfallerMARempeLE, et al.Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA1991; 265: 2364–2368.
19.
RaadIDarouicheRDupuisJ, et al.Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med1997; 127: 267–274.
20.
TagliettiAArciolaCRD’AgostinoA, et al.Antibiofilm activity of a monolayer of silver nanoparticles anchored to an amino-silanized glass surface. Biomaterials2014; 35: 1779–1788.
21.
SampathLATambeSMModakSM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol2001; 22: 640–646.
22.
GallieniMBrennaIBruniniF, et al.Dialysis central venous catheter types and performance. J Vasc Access2014; 15: S140–S146.
23.
NguyenKCRichardsLMassarskyA, et al.Toxicological evaluation of representative silver nanoparticles in macrophages and epithelial cells. Toxicol In Vitro2016; 33: 163–173.
24.
PercivalSLBowlerPGRussellD. Bacterial resistance to silver in wound care. J Hosp Infect2005; 60: 1–7.
25.
SütterlinSEdquistPSandegrenL, et al.Silver resistance genes are overrepresented among Escherichia coli isolates with CTX-M production. Appl Environ Microbiol2014; 80: 6863–6869.
26.
ChenYMDaiAPShiY, et al.Effectiveness of silver-impregnated central venous catheters for preventing catheter-related blood stream infections: a meta-analysis. Int J Infect Dis2014; 29: 279–286.
27.
TanCPCraigheadHG. Surface engineering and patterning using parylene for biological applications. Materials2010; 3: 1803–1832.
28.
BalazsDJTriandafilluKChevolotY, et al.Surface modification of PVC endotracheal tubes by oxygen glow discharge to reduce bacterial adhesion. Surf Interface Anal2003; 35: 301–309.
29.
ChoudhuryAJGogoiDKandimallaR, et al.Penicillin impregnation on oxygen plasma surface functionalized chitosan/Antheraea assama silk fibroin: studies of antibacterial activity and antithrombogenic property. Mater Sci Eng C Mater Biol Appl2016; 60: 475–484.
30.
PieleszAMachnickaASE. Antibacterial activity and scanning electron microscopy (SEM) examination of alginate-based films and wound dressings. Ecol Chem Eng S2011; 18: 197–210.
31.
GohCHHengPWSHuangEPE, et al.Interactions of antimicrobial compounds with cross-linking agents of alginate dressings. J Antimicrob Chemother2008; 62: 105–108.
32.
FuJJiJYuanW, et al.Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials2005; 26: 6684–6692.
33.
DashMChielliniFOttenbriteRM, et al.Chitosan-A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci2011; 36: 981–1014.
34.
Yi H, Wu L-Q, Bentley WE, et al. Biofabrication with chitosan. Biomacromolecules 2005; 6: 2881–2894.
MuHGuoFNiuH, et al.Chitosan improves anti-biofilm efficacy of gentamicin through facilitating antibiotic penetration. Int J Mol Sci2014; 15: 22296–22308.
37.
NoH. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int J Food Microbiol2002; 74: 65–72.
38.
RabeaEIBadawyMETStevensCV, et al.Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules, 4, 2003, pp. 1457–1465.
39.
Ravi KumarMN. A review of chitin and chitosan applications. React Funct Polym2000; 46: 1–27.
40.
Costa-PintoARMartinsAMCastelhano-CarlosMJ, et al.In vitro degradation and in vivo biocompatibility of chitosan-poly(butylene succinate) fiber mesh scaffolds. J Bioact Compat Polym2014; 29: 137–151.
41.
MachulAMikołajczykDRegiel-FutyraA, et al.Study on inhibitory activity of chitosan-based materials against biofilm producing Pseudomonas aeruginosa strains. J Biomater Appl2015; 30: 269–278.
42.
ShalumonKTAnulekhaKHNairSV, et al.Sodium alginate/poly(vinyl alcohol)/nano ZnO composite nanofibers for antibacterial wound dressings. Int J Biol Macromol2011; 49: 247–254.
43.
BumgardnerJDWiserRGerardPD, et al.Chitosan: potential use as a bioactive coating for orthopaedic and craniofacial/dental implants. J Biomater Sci Polym Ed2003; 14: 423–438.
44.
RaafatDvon BargenKHaasA, et al.Insights into the mode of action of chitosan as an antibacterial compound. Appl Environ Microbiol2008; 74: 3764–3773.
45.
WangXZhuK-XZhouH-M. Immobilization of glucose oxidase in alginate-chitosan microcapsules. Int J Mol Sci2011; 12: 3042–3054.
46.
WeeSGombotzW. Protein release from alginate matrices. Adv Drug Deliv Rev1998; 31: 267–285.
47.
WangLSheltonRMCooperPR, et al.Evaluation of sodium alginate for bone marrow cell tissue engineering. Biomaterials2003; 24: 3475–3481.
48.
MotwaniSChopraSTalegaonkarS, et al.Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm2007; 68: 513–525.
49.
RegielAIrustaSKyziołA, et al.Preparation and characterization of chitosan-silver nanocomposite films and their antibacterial activity against Staphylococcus aureus. Nanotechnology2013; 24: 15101–15101.
50.
Aegerter MA and Mennig M (eds) Sol–gel technologies for glass producers and users. Boston, MA: Springer US, 2004, pp.38–48.
51.
MermelLAAllonMBouzaE, et al.Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis2009; 49: 1–45.
52.
ButrukBZiętekPCiachT. Simple method of fabrication of hydrophobic coatings for polyurethanes. Open Chem2011; 9: 1039–1039.
53.
WeyermannJLochmannDZimmerA. A practical note on the use of cytotoxicity assays. Int J Pharm2005; 288: 369–376.
TorabiSMahdavianARSaneiM, et al.Chitosan and functionalized acrylic nanoparticles as the precursor of new generation of bio-based antibacterial films. Mater Sci Eng C Mater Biol Appl2016; 59: 1–9.
56.
KhanIUSerraCAAntonN, et al.Continuous-flow encapsulation of ketoprofen in copolymer microbeads via co-axial microfluidic device: influence of operating and material parameters on drug carrier properties. Int J Pharm2013; 441: 809–817.
57.
RanjhaNMAyubGNaseemS, et al.Preparation and characterization of hybrid pH-sensitive hydrogels of chitosan-co-acrylic acid for controlled release of verapamil. J Mater Sci Mater Med2010; 21: 2805–2816.
58.
AlmeidaEVRFrolliniECastellanA, et al.Chitosan, sisal cellulose, and biocomposite chitosan/sisal cellulose films prepared from thiourea/NaOH aqueous solution. Carbohydr Polym2010; 80: 655–664.
59.
ChenCHWangFYMaoCF, et al.Studies of chitosan: II. Preparation and characterization of chitosan/poly(vinyl alcohol)/gelatin ternary blend films. Int J Biol Macromol2008; 43: 37–42.
60.
ChenCFWangFYMaoCF, et al.Studies of chitosan. I. Preparation and characterization of chitosan/poly(vinyl alcohol) blend films. J Appl Polym Sci2007; 105: 1086–1092.
61.
WangXXiZLiuZ, et al.The fabrication and property of hydrophilic and hydrophobic double functional bionic chitosan film. J Nanosci Nanotechnol2011; 11: 9737–9740.
62.
GilbertREHardenM. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis2008; 21: 235–245.
63.
RaiAPintoSEvangelistaMB, et al.High-density antimicrobial peptide coating with broad activity and low cytotoxicity against human cells. Acta Biomater2016; 33: 64–77.
64.
SeussSLehmannMBoccacciniAR. Alternating current electrophoretic deposition of antibacterial bioactive glass-chitosan composite coatings. Int J Mol Sci2014; 15: 12231–41222.
65.
Regiel-FutyraAKus-LiśkiewiczMSebastianV, et al.Development of noncytotoxic chitosan-gold nanocomposites as efficient antibacterial materials. ACS Appl Mater Interfaces2015; 7: 1087–1099.
66.
JeJYKimSK. Chitosan derivatives killed bacteria by disrupting the outer and inner membrane. J Agric Food Chem2006; 54: 6629–6633.
67.
CueroRGOsujiGWashingtonA. N-carboxymethylchitosan inhibition of aflatoxin production: role of zinc. Biotechnol Lett1991; 13: 441–444.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
